OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study

Overview of attention for article published in SpringerPlus, December 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 62 Dimensions

Readers on

mendeley: 38 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Erenumab for preventing migraine : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 19 Sep 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health on 03 Jan 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.